Genitourinary Cancers

Che-Kai Tsao, MD, discusses the current unmet needs in adjuvant therapy for patients with renal cell carcinoma and how current research is addressing such challenges.

In metastatic renal cell carcinoma, the use of frontline combination immunotherapy regimens has led to significant survival benefits for patients, and efforts are now being focused on exploring novel options for those who become refractory to this approach.

Reza Mehrazin, MD, discusses the need for more research before determining the role of cytoreductive nephrectomy in an era of immunotherapy and targeted therapy.

Daniel P. Petrylak, MD, discusses available treatment options in metastatic bladder cancer.

The United Kingdom’s National Institute for Health and Care Excellence has chosen not to recommend pembrolizumab as a treatment for patients with locally advanced or metastatic urothelial carcinoma who have previously received platinum-containing chemotherapy.

Toni K. Choueiri, MD, discusses the safety profile of the oral HIF-2α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma.

Chung-Han (Joe) Lee, MD, PhD, discussed advancements in metastatic renal cell carcinoma regarding combination regimens and ongoing questions of how to treat patients upon disease progression.

Che-Kai Tsao, MD, discusses the rationale behind staging disease, especially in the context of when patients are diagnosed with renal cell carcinoma.

Adjuvant platinum-based chemotherapy reduced the risk of disease recurrence or death by 55% in patients with upper tract urothelial carcinoma, according to findings from the phase III POUT trial that have now been published in The Lancet.

Durvalumab alone did not improve overall survival compared with standard-of-care chemotherapy in patients with unresectable urothelial cancer whose tumors had high levels (≥25%) of PD-L1 expression, missing both primary endpoints of the phase III DANUBE trial.

David F. McDermott, MD, discusses the research behind combining VEGF inhibitors with PD-1/PD-L1 inhibitors in renal cell carcinoma treatment.

Arjun V. Balar, MD, discusses how immunotherapy options are helping to reduce reliance on platinum chemotherapy and cystectomy, as well as further efforts to engage the immune system in the fight against bladder cancer and other pathways toward greater treatment efficacy and quality of life for patients.

Chung-Han Lee, MD, PhD, discusses treatment options for patients with metastatic renal cell carcinoma.

Robert A. Figlin, MD, discusses novel combinations in the treatment of patients with kidney cancer.

Bradley McGregor, MD, discusses combination therapies with nivolumab, cabozantinib, and sunitinib in renal cell carcinoma.

Thomas Powles, MD, MBBS, MRCP, discusses the mission and goals for the Uromigos Twitter group.

Bradley McGregor, MD, discusses enfortumab vedotin-ejfv’s path to approval and its future potential in bladder cancer.

Monika Joshi, MD, discusses durvalumab (Imfinzi) and radiation therapy (DUART) in locally advanced urothelial cancer of the bladder.

Martin H. Voss, MD, discusses the phase I/II trial evaluating MEDI0680 plus durvalumab in metastatic renal cell carcinoma and what similar research efforts lie ahead.

The FDA has granted a breakthrough therapy designation to the combination of enfortumab vedotin-ejfv and pembrolizumab as a first-line treatment of patients with unresectable locally advanced or metastatic urothelial cancer who are unable to receive cisplatin-based chemotherapy.

Ziad Bakouny, MD, MSc, discusses the role of cytoreductive nephrectomy in metastatic renal cell carcinoma.

Ulka Vaishampayan, MD, discusses the considerations when giving patients with metastatic renal cell carcinoma systemic therapy followed by cytoreductive nephrectomy.

Daniel P. Petrylak, MD, discusses important new developments in bladder and prostate cancer.

Toni K. Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, and Jerome and Nancy Kohlberg Chair and professor of medicine, Harvard Medical School, discusses phase I/II results of a trial evaluating the oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma.

Ajjai Shivaram Alva, MBBS, discusses the shift toward combination therapy versus monotherapy in metastatic renal cell carcinoma.